Csenge Advisory Group Buys 3,267 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Csenge Advisory Group increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 144.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,527 shares of the medical equipment provider's stock after buying an additional 3,267 shares during the period. Csenge Advisory Group's holdings in Intuitive Surgical were worth $2,668,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after purchasing an additional 731 shares in the last quarter. Bank Pictet & Cie Europe AG raised its position in Intuitive Surgical by 0.5% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after purchasing an additional 883 shares in the last quarter. Proficio Capital Partners LLC raised its position in Intuitive Surgical by 70.9% during the fourth quarter. Proficio Capital Partners LLC now owns 1,820 shares of the medical equipment provider's stock valued at $950,000 after purchasing an additional 755 shares in the last quarter. TD Private Client Wealth LLC raised its position in Intuitive Surgical by 8.1% during the fourth quarter. TD Private Client Wealth LLC now owns 3,988 shares of the medical equipment provider's stock valued at $2,082,000 after purchasing an additional 299 shares in the last quarter. Finally, ZEGA Investments LLC acquired a new position in Intuitive Surgical during the fourth quarter valued at approximately $1,163,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $2.46 on Friday, reaching $518.62. The company had a trading volume of 1,903,997 shares, compared to its average volume of 1,666,315. The firm has a market cap of $185.88 billion, a price-to-earnings ratio of 76.04, a P/E/G ratio of 5.50 and a beta of 1.64. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The business has a 50 day moving average of $535.90 and a two-hundred day moving average of $536.21.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The business had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period in the prior year, the business posted $1.50 earnings per share. As a group, research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on ISRG. Barclays lowered their price objective on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their price objective for the company from $515.00 to $440.00 in a research report on Monday, June 9th. BTIG Research set a $566.00 price objective on shares of Intuitive Surgical and gave the company a "buy" rating in a research report on Monday, July 14th. Citigroup restated a "buy" rating and set a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Finally, Truist Financial lowered their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and a consensus target price of $592.86.

Insider Activity

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the sale, the executive vice president owned 2,245 shares of the company's stock, valued at approximately $1,152,089.10. This represents a 43.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jami K. Nachtsheim sold 2,400 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the sale, the director directly owned 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,998 shares of company stock worth $2,611,577. 0.70% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.